Tigecycline is a member of the
glycylcycline class of antimicrobials, which is structurally similar to the
tetracycline class. It demonstrates potent in vitro activity against causative pathogens that are most frequently isolated in patients with community-acquired
bacterial pneumonia (CABP), including (but not limited to) Streptococcus pneumoniae (both
penicillin-sensitive and -resistant strains), Haemophilus influenzae and Moraxella catarrhalis (including β-lactamase-producing strains), Klebsiella pneumoniae, and 'atypical organisms' (namely Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila). Comparative randomized clinical trials to date performed in hospitalized patients receiving
tigecycline 100 mg intravenous (IV) × 1 and then 50 mg IV twice daily thereafter have demonstrated efficacy and safety comparable to the comparator agent. Major adverse effects were primarily gastrointestinal in nature.
Tigecycline represents a parenteral monotherapy option in hospitalized patients with CABP (especially in patients unable to receive respiratory
fluoroquinolones). However, alternate and/or additional
therapies should be considered in patients with more severe forms of CABP in light of recent data of increased mortality in patients receiving
tigecycline for other types of severe
infection.